Clinical Research Directory
Browse clinical research sites, groups, and studies.
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Summary
The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Official title: The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
27
Start Date
2021-07-19
Completion Date
2025-12-01
Last Updated
2024-12-20
Healthy Volunteers
No
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Dupilumab will be administered subcutaneously for 6 months (1 initial 600mg dose + 5 300mg doses every 4 weeks)
Locations (1)
St. Joseph's Health Care
London, Ontario, Canada